A5042957984- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- melanin and skin pigmentation
- Melanoma and MAPK Pathways
- Sarcoidosis and Beryllium Toxicity Research
- Genetic Associations and Epidemiology
- Cutaneous Melanoma Detection and Management
- Epigenetics and DNA Methylation
- Occupational and environmental lung diseases
- Medical Imaging and Pathology Studies
- Systemic Sclerosis and Related Diseases
- Cancer Genomics and Diagnostics
- Genomics and Chromatin Dynamics
- Photodynamic Therapy Research Studies
- Pulmonary Hypertension Research and Treatments
- Skin Protection and Aging
- RNA regulation and disease
- Renal cell carcinoma treatment
- Nuclear Structure and Function
- Eosinophilic Disorders and Syndromes
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Telomeres, Telomerase, and Senescence
- Occupational exposure and asthma
- Inhalation and Respiratory Drug Delivery
- Protein Degradation and Inhibitors
- Nanoplatforms for cancer theranostics
National Cancer Institute
2016-2025
Division of Cancer Epidemiology and Genetics
2016-2025
National Institutes of Health
2015-2024
University of Colorado Denver
2015-2024
University of Toronto
2019-2024
National Jewish Health
2015-2024
Public Health Ontario
2024
3M (United States)
2024
Center for Cancer Research
2024
Wildlife Conservation Society United Kingdom
2024
Section:ChooseTop of pageAbstract <<CONTENTSOBJECTIVEMETHODSSIGNIFICANCE OF EVIDENCE-...SUMMARY CONCLUSIONS AND T...DEFINITION EPIDEMIOLO...DEFINITION UIP PATTERNDIAGNOSISNATURAL HISTORY IPFSTAGING PROGNOSISTREATMENTTREATMENT SELECTED COM...PALLIATIVE CAREMONITORING THE CLINICAL C...FUTURE DIRECTIONSReferencesCITING ARTICLES
Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients idiopathic pulmonary fibrosis.We conducted two replicate 52-week, randomized, double-blind, 3 trials (INPULSIS-1 INPULSIS-2) to evaluate the efficacy safety compared placebo fibrosis. The primary end point was annual rate forced vital capacity...
Section:ChooseTop of pageAbstract <<ContentsExecutive SummaryIntroductionMethodsSummary Major Revision...General Progress in IIPs ...Important Differential Di...Progress Specific IIPs...Rare IIPsRare Histologic PatternsUnclassifiable IIPClinical Classification o...BiomarkersReferencesCITING ARTICLES
This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between American Thoracic Society, European Respiratory Japanese and Latin Society.The evidence syntheses were discussed formulated by multidisciplinary committee IPF experts. The was appraised formulated, written, graded using Grading Recommendations, Assessment, Development, Evaluation approach.The guideline panel updated diagnostic criteria IPF....
The mutations that have been implicated in pulmonary fibrosis account for only a small proportion of the population risk.
Idiopathic pulmonary fibrosis is a progressive lung disease with high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in fibrosis, it has suggested that inhibition of these may slow progression idiopathic fibrosis.In 12-month, phase 2 trial, we assessed efficacy and safety four different oral doses inhibitor BIBF 1120 as compared placebo patients fibrosis. The primary end point was annual rate decline forced vital...
Section:ChooseTop of pageAbstract <<ContentsExecutive SummaryIntroductionMethodsBal Cellular Analyses as ...Performing, Handling, and...Bal Analysis In ...Conclusions and Future Di...Note From ATS Documents E...ReferencesCITING ARTICLES
Many patients with an idiopathic interstitial pneumonia (IIP) have clinical features that suggest underlying autoimmune process but do not meet established criteria for a connective tissue disease (CTD). Researchers proposed differing and terms to describe these patients, lack of consensus over nomenclature classification limits the ability conduct prospective studies uniform cohort. The “European Respiratory Society/American Thoracic Society Task Force on Undifferentiated Forms Connective...
Background —Familial polymorphic ventricular tachycardia is an autosomal-dominant, inherited disease with a relatively early onset and mortality rate of ≈30% by the age 30 years. Phenotypically, it characterized salvoes bidirectional tachycardias in response to vigorous exercise, no structural evidence myocardial disease. We previously mapped causative gene chromosome 1q42-q43. In present study, we demonstrate that patients familial have missense mutations cardiac sarcoplasmic reticulum...
A previous trial of bosentan in idiopathic pulmonary fibrosis (IPF) showed a trend to delayed IPF worsening or death. Also, improvements some measures dyspnea and health-related quality life were observed.To demonstrate that delays death.Prospective, randomized (2:1), double-blind, placebo-controlled, event-driven, parallel-group, morbidity-mortality adults with less than 3 years' duration, confirmed by surgical lung biopsy, without extensive honeycombing on high-resolution computed...
It is hypothesized that the extent and severity of fibrosis cellularity found on lung biopsy determine prognosis response to therapy in idiopathic pulmonary (IPF). The objective this study was which histopathologic features predict survival IPF. We prospectively studied 87 patients with usual interstitial pneumonia (UIP) confirmed by surgical biopsy. Four pathologists independently graded specific features. used Cox proportional-hazards models assess effect patterns patients' survival....
Background: Prospective data defining the clinical course in idiopathic pulmonary fibrosis (IPF) are sparse. Objective: To analyze of patients with mild to moderate IPF. Design: Analysis from placebo group a randomized, controlled trial evaluating interferon-γ1b. Setting: Academic and community medical centers. Patients: 168 Measurements: Measures physiology dyspnea assessed at 12-week intervals; hospitalizations; pace deterioration cause death over median period 76 weeks. Results:...
High-resolution computed tomography (HRCT) is an integral aspect of the evaluation patients with suspected idiopathic pulmonary fibrosis (IPF). However, few studies have evaluated its use in a large cohort.To describe HRCT features mild to moderate IPF, compare diagnostic evaluations by radiology core (three thoracic radiologists) those study-site radiologists, correlate baseline clinical and physiologic variables findings, evaluate their association mortality.We assessed scans from IPF (n =...
Chinese translation This article has been corrected. The original version (PDF) is appended to this as a Supplement. Background: Idiopathic pulmonary fibrosis (IPF) characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung contractile activity via the endothelin A (ETA) receptor. Objective: To determine whether ambrisentan, an ETA receptor–selective antagonist, reduces rate IPF progression. Design: Randomized, double-blind, placebo-controlled, event-driven...
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease lacking effective treatment.Objectives: To determine the effects of bosentan on exercise capacity and time to progression in patients with IPF.Methods: In double-blind, multicenter trial, IPF were randomized receive oral 62.5 mg twice daily for 4 weeks, increased 125 thereafter, or placebo, 12 months longer. The primary efficacy endpoint was change from baseline up Month capacity, as measured by modified...
Mortality rates from rheumatoid arthritis-associated interstitial lung disease (RA-ILD) are largely unknown.We sought to determine mortality in the United States 1988 through 2004.Using data National Center for Health Statistics, we calculated age-adjusted deaths of persons with disease, determined prevalence all decedents arthritis, and compared age underlying cause death these two cohorts decedents.From 2004, there were 39,138,394 U.S. residents 162,032 deaths. Of deaths, 10,725 (6.6%) met...
So far, two genes associated with familial melanoma have been identified, accounting for a minority of genetic risk in families. Mutations CDKN2A account approximately 40% cases, and predisposing mutations CDK4 reported very small number kindreds. Here we report the whole-genome sequencing probands from several families, which performed order to identify other melanoma. We one individual carrying novel germline variant (coding DNA sequence c.G1075A; protein p.E318K; rs149617956)...